Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
South Africa
DRUG PRODUCT COMPOSITIONS
Regulatory FDF Prices
NA
0
Weekly News Recap #Phispers


1. Gtpl9416
2. Isis396443
| Molecular Weight | 7127 g/mol |
|---|---|
| Molecular Formula | C234H340N61O128P17S17 |
| XLogP3 | -14.4 |
| Hydrogen Bond Donor Count | 40 |
| Hydrogen Bond Acceptor Count | 167 |
| Rotatable Bond Count | 176 |
| Exact Mass | 7124.2829700 g/mol |
| Monoisotopic Mass | 7122.2762603 g/mol |
| Topological Polar Surface Area | 2820 Ų |
| Heavy Atom Count | 457 |
| Formal Charge | 0 |
| Complexity | 19100 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 72 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 43092
Submission : 2025-11-20
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 42251
Submission : 2025-07-07
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41696
Submission : 2025-04-17
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41707
Submission : 2025-03-28
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 43283
Submission : 2025-12-26
Status : Active
Type : II

USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 42326
Submission : 2025-08-05
Status : Active
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC Package Code : 71860-396
Start Marketing Date : 2016-12-23
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : Transo-Pharm is a licensed distributor of pharmaceutical components for human and veterinary markets. The company supports the full API life cycle, from development to sales, and a...
About the Company : Aspen API is a cooperative entity formed by Aspen Oss in the Netherlands and Fine Chemicals Corporation in South Africa. The company supplies a broad portfolio of over 50 high-qual...
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
About the Company : Pharmathen, established in 1969, has emerged as a leading in-house development partner in Europe. It specializes in the development, registration, manufacturing & life-cycle manage...
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
About the Company : Omgene Life Sciences Pvt. Ltd. is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integ...
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
About the Company : Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios ...
About the Company : Anhui Ribobay Pharmaceutical Co., Ltd., known as Ribobay, was established in August 2021 as a fully owned subsidiary of General Biol. Situated in the Quanjiao industry Zone in Chuz...

About the Company : Sinopep leads the industry in therapeutic peptides, supplying top-demand APIs like Albuvirtide, Lanreotide, Semaglutide, and more. Renowned for high-quality peptide APIs and effici...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nusinersen Sodium is a oligonucleotide drug, which is currently being evaluated in Approved FDF clinical studies for the treatment of muscular atrophy, spinal.
Lead Product(s): Nusinersen,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 30, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nusinersen,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Fda Approves High Dose Regimen of SPINRAZA for Spinal Muscular Atrophy
Details : Nusinersen Sodium is a oligonucleotide drug, which is currently being evaluated in Approved FDF clinical studies for the treatment of muscular atrophy, spinal.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 30, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nusinersen Sodium, an oligonucleotide targeting SMN2 pre-mRNA, shows promise in treating 5q spinal muscular atrophy (SMA).
Lead Product(s): Nusinersen,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Spinraza
Study Phase: Approved FDFProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 12, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nusinersen,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biogen Receives EU Approval for High-Dose SPINRAZA in Spinal Muscular Atrophy
Details : Nusinersen Sodium, an oligonucleotide targeting SMN2 pre-mRNA, shows promise in treating 5q spinal muscular atrophy (SMA).
Product Name : Spinraza
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
January 12, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Apitegromab is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Muscular Atrophy, Spinal.
Lead Product(s): Apitegromab,Nusinersen,Risdiplam
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 02, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Apitegromab,Nusinersen,Risdiplam
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Apitegromab Mechanism in Subjects <2 Years with Spinal Muscular Atrophy
Details : Apitegromab is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Muscular Atrophy, Spinal.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 02, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and Toddlers.
Lead Product(s): Nusinersen,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Spinraza
Study Phase: Approved FDFProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 23, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nusinersen,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
Details : Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and Toddlers.
Product Name : Spinraza
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
January 23, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and Toddlers.
Lead Product(s): Nusinersen,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Spinraza
Study Phase: Phase II/ Phase IIIProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 09, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nusinersen,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biogen Reports Promising Results For Higher Dose of Spinraza
Details : Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and Toddlers.
Product Name : Spinraza
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
October 09, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Lantesens (nusinersen) is a generic of Spinraza, which is SMN2-directed antisense oligonucleotide investigated for the treatment of spinal muscular atrophy (SMA) in pediatrics.
Lead Product(s): Nusinersen,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Spinraza
Study Phase: Phase II/ Phase IIIProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 04, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nusinersen,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biogen Reports Positive Topline Results For Higher Dose Of Nusinersen in SMA
Details : Lantesens (nusinersen) is a generic of Spinraza, which is SMN2-directed antisense oligonucleotide investigated for the treatment of spinal muscular atrophy (SMA) in pediatrics.
Product Name : Spinraza
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
September 04, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nusinersen is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Muscular Atrophy, Spinal.
Lead Product(s): Nusinersen,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 15, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nusinersen,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRxâ...
Details : Nusinersen is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Muscular Atrophy, Spinal.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
August 15, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Lantesens (nusinersen) is a generic of Spinraza, which is SMN2-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Lead Product(s): Nusinersen,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Lantesens
Study Phase: Approved FDFProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 14, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nusinersen,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Russia registers domestic generic of Spinraza
Details : Lantesens (nusinersen) is a generic of Spinraza, which is SMN2-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Product Name : Lantesens
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
May 14, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Lead Product(s): Nusinersen,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Spinraza
Study Phase: Phase IVProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 06, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nusinersen,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
New Biomarker Data Support Potential Benefit of SPINRAZA in Infants
Details : Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Product Name : Spinraza
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 06, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
SPINRAZA (nusinersen) is an antisense oligonucleotide (ASO) that targets the root cause of SMA by continuously increasing the amount of full-length survival motor neuron (SMN) protein produced in the body.
Lead Product(s): Nusinersen,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Spinraza
Study Phase: Approved FDFProduct Type: Oligonucleotide
Sponsor: Biogen
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 27, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nusinersen,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SPINRAZA (nusinersen) is an antisense oligonucleotide (ASO) that targets the root cause of SMA by continuously increasing the amount of full-length survival motor neuron (SMN) protein produced in the body.
Product Name : Spinraza
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
June 27, 2023

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : USA
Registration Country : Greece
Brand Name :
Dosage Form : Solution For Injection
Dosage Strength : 12MG/5ML
Packaging :
Approval Date :
Application Number :
Regulatory Info : USA
Registration Country : Greece
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : SPINRAZA
Dosage Form : SOLUTION;INTRATHECAL
Dosage Strength : EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML)
Packaging :
Approval Date : 2016-12-23
Application Number : 209531
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Spinraza
Dosage Form : Solution For Injection
Dosage Strength : 12mg/5ml
Packaging :
Approval Date : 20/09/2017
Application Number : 66495
Regulatory Info : Allowed
Registration Country : Switzerland

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Marketed
Registration Country : Norway
Brand Name : Spinraza
Dosage Form : Solution For Injection
Dosage Strength : 12mg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Marketed
Registration Country : Norway

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Estonia
Brand Name : Spinraza
Dosage Form : Solution For Injection
Dosage Strength : 24mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info : Prescription
Registration Country : Estonia

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Spinraza
Dosage Form : Injectable Solution
Dosage Strength : 12MG
Packaging :
Approval Date : 06-07-2017
Application Number : 1171188001
Regulatory Info : Authorized
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Spinraza
Dosage Form : Injection Solution
Dosage Strength : 2.4mg/ml
Packaging :
Approval Date : 30-05-2017
Application Number : 28105860816
Regulatory Info : Prescription
Registration Country : Denmark

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Spinraza
Dosage Form : Injectable Solution
Dosage Strength : 12mg
Packaging :
Approval Date : 30-05-2017
Application Number : 2.02E+13
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : PRESCRIPTION
Registration Country : Canada
NUSINERSEN (NUSINERSEN SODIUM)
Brand Name : SPINRAZA
Dosage Form : SOLUTION
Dosage Strength : 2.4MG/ML
Packaging : 5ML
Approval Date :
Application Number : 2465663
Regulatory Info : PRESCRIPTION
Registration Country : Canada

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Australia
Brand Name : Spinraza
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
62
PharmaCompass offers a list of Nusinersen API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Nusinersen manufacturer or Nusinersen supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Nusinersen manufacturer or Nusinersen supplier.
A Nusinersen manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nusinersen, including repackagers and relabelers. The FDA regulates Nusinersen manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nusinersen API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nusinersen manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Nusinersen supplier is an individual or a company that provides Nusinersen active pharmaceutical ingredient (API) or Nusinersen finished formulations upon request. The Nusinersen suppliers may include Nusinersen API manufacturers, exporters, distributors and traders.
click here to find a list of Nusinersen suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Nusinersen DMF (Drug Master File) is a document detailing the whole manufacturing process of Nusinersen active pharmaceutical ingredient (API) in detail. Different forms of Nusinersen DMFs exist exist since differing nations have different regulations, such as Nusinersen USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Nusinersen DMF submitted to regulatory agencies in the US is known as a USDMF. Nusinersen USDMF includes data on Nusinersen's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nusinersen USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Nusinersen suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nusinersen as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Nusinersen API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Nusinersen as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Nusinersen and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nusinersen NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Nusinersen suppliers with NDC on PharmaCompass.
Nusinersen Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nusinersen GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Nusinersen GMP manufacturer or Nusinersen GMP API supplier for your needs.
A Nusinersen CoA (Certificate of Analysis) is a formal document that attests to Nusinersen's compliance with Nusinersen specifications and serves as a tool for batch-level quality control.
Nusinersen CoA mostly includes findings from lab analyses of a specific batch. For each Nusinersen CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nusinersen may be tested according to a variety of international standards, such as European Pharmacopoeia (Nusinersen EP), Nusinersen JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nusinersen USP).